Conjunctival Stromal Tumor: Report of 2 New Cases and Review of the Literature

Jonathan Lam, Andrea Ang, Tersia Vermeulen, Nima Mesbah Ardakani

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Conjunctival stromal tumor (COST) is an emerging entity with only a limited number of cases reported in the literature. In this report, we describe 2 additional cases, review the accumulative clinical and histopathological features and expand on the immunophenotypic property of this entity. COST appears to have a sporadic presentation, affecting both sexes and patients of variable ethnicity and age group and predominantly occurring on the bulbar conjunctiva as a slow-growing asymptomatic or slightly tender mass-like lesion. Histopathologically, COST is characterized by singly dispersed spindle to round cells, often with some degree of degenerative nuclear atypia, within a myxomatous to collagenous stroma. Lesional cells are characteristically positive for CD34 and vimentin, negative for S100, SOX10 and STAT6 and show a normal pattern of staining with RB1 by immunohistochemistry. The reported cases to date have shown an indolent biological behavior, reliably treated by a complete surgical excision.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalInternational Journal of Surgical Pathology
Issue number3
Early online date29 Jul 2020
Publication statusPublished - May 2021


Dive into the research topics of 'Conjunctival Stromal Tumor: Report of 2 New Cases and Review of the Literature'. Together they form a unique fingerprint.

Cite this